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A B S T R A C T
Purpose
Medulloblastoma comprises four distinct molecular subgroups: WNT, SHH, Group 3, and Group 4.
Current medulloblastoma protocols stratify patients based on clinical features: patient age,
metastatic stage, extent of resection, and histologic variant. Stark prognostic and genetic
differences among the four subgroups suggest that subgroup-specific molecular biomarkers could
improve patient prognostication.
Patients and Methods
Molecular biomarkers were identified from a discovery set of 673 medulloblastomas from 43 cities
around the world. Combined risk stratification models were designed based on clinical and
cytogenetic biomarkers identified by multivariable Cox proportional hazards analyses. Identified
biomarkers were tested using fluorescent in situ hybridization (FISH) on a nonoverlapping
medulloblastoma tissue microarray (n  453), with subsequent validation of the risk stratifica-
tion models.
Results
Subgroup information improves the predictive accuracy of a multivariable survival model
compared with clinical biomarkers alone. Most previously published cytogenetic biomarkers
are only prognostic within a single medulloblastoma subgroup. Profiling six FISH biomarkers
(GLI2, MYC, chromosome 11 [chr11], chr14, 17p, and 17q) on formalin-fixed paraffin-embedded tissues,
we can reliably and reproducibly identify very low-risk and very high-risk patients within SHH, Group 3, and
Group 4 medulloblastomas.
Conclusion
Combining subgroup and cytogenetic biomarkers with established clinical biomarkers substantially
improves patient prognostication, even in the context of heterogeneous clinical therapies. The
prognostic significance of most molecular biomarkers is restricted to a specific subgroup. We have
identified a small panel of cytogenetic biomarkers that reliably identifies very high-risk and very
low-risk groups of patients, making it an excellent tool for selecting patients for therapy
intensification and therapy de-escalation in future clinical trials.
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INTRODUCTION
Medulloblastoma, the most commonmalignant childhood brain tu-
mor, is an embryonal tumorwith a peak incidence in early childhood.
Current therapy entails surgical resection, craniospinal irradiation,
and high-dose chemotherapy. Risk stratification is based primarily
on clinical variables, with high-risk patients identified as having
leptomeningeal metastases at presentation and/or an incomplete
resection.1-3 Unfortunately, most survivors are left with long-term
disabilities secondary to the disease and treatment.4-6 Clinicians
have hypothesized that improved patient prognostication could
enable therapy intensification in high-risk patients and therapy
de-escalation to maximize quality of life in lower-risk patients.
Numerous publications have attempted to identify biomarkers
toeither supportor supplantclinical risk stratification.2,7-14Mutations
of specific genes such as CTNNB and TP53 have shown prognostic
significance.15-19 Additional candidates include medulloblastoma-
overexpressed genes such as TRKC, ERBB2, and FSTL5.20-25 Several
DNAcopy-numberaberrationshavealsobeenpurportedasbiomark-
ers, although the results have often been conflicting.15,26-48 These
aberrations are summarized in Table 1. Few of these putative molec-
ular biomarkers have been validated in prospective clinical trials.
It is now recognized that medulloblastoma is a collection of
heterogeneous entities with disparate demographics, transcriptomes,
genetics, and clinical outcomes.2,28,32,49-60 According to international
consensus, the principle subgroups of medulloblastoma are WNT,
SHH, Group 3, and Group 4.52 Because earlier prognostic biomarker
studies did not account for these subgroups, we hypothesized that
some of the disparate biomarker findings could have resulted from
differential subgroup representation among studies. Several previ-
ously reported biomarkers were in fact enriched within a specific
subgroup of the disease (eg, monosomy 6 in WNT tumors, MYC
amplification in Group 3 tumors). In cases where a biomarker is
prognostic across all medulloblastomas, but the prognostic impact is
driven by a single subgroup, we suggest that themarker be designated
as subgroup driven. These surrogate markers are replaceable by sub-
group status. In cases where a biomarker is variably or not effective
across the spectrum of medulloblastomas but is valid only within a
specific subgroup, we suggest that it be designated as subgroup spe-
cific. Such biomarkers are prognostically informative onlywithin spe-
cific medulloblastoma subgroups.
To determine whether subgroup affiliation and cytogenetic bio-
markers could support or supplant clinical variables for prognostica-
tion in patientswithmedulloblastoma,we assembled an international
discovery cohort of 673medulloblastomas throughMAGIC (Medul-
loblastoma Advanced Genomics International Consortium), for
which we had both clinical follow-up and whole-genome copy-
numberdata.Tobegin,we identified subgroup-specific copy-number
aberrations (CNAs) and integrated them with clinical variables to
develop subgroup-specific riskmodels based on the discovery cohort.
To validate our models and ensure that our technique was generaliz-
able to routine pathology laboratories, we then studied a panel of six
cytogenetic biomarkers (GLI2,MYC, chromosome 11 [chr11], chr14,
17p, and 17q) using interphase fluorescent in situ hybridization
(FISH) on a formalin-fixed paraffin-embedded (FFPE) medulloblas-
toma tissue microarray (TMA) that included 453 medulloblastomas
treatedat a single center anddidnotoverlapwith thediscoverycohort.
Our analysis of 1,000 patientswithmedulloblastoma clearly
demonstrates that subgroup affiliation can improve prognostica-
tion with clinical variables and that a majority of publishedmolec-
ular biomarkers are relevant only within a single subgroup. The
combination of clinical variables, subgroup affiliation, and six
cytogenetic markers analyzed on FFPE tissues can achieve an un-
precedented level of prognostic prediction for patients that is prac-
tical, reliable, and reproducible.
PATIENTS AND METHODS
Tumor Material and Patient Characteristics
A discovery set of 673medulloblastoma samples with clinical follow-up
was acquired retrospectively from 43 cities around the world. These samples
Table 1. Previously Reported Prognostic Molecular Markers in MB
Marker
Previous Studies Our Study
Cohort Prognosis Validated MB (P) SHH (P) Group 3 (P) Group 4 (P)
1q gain MB26,27 Poor No .61 .59 .018 .33
Chr2 gain SHH30 Poor No .16 .66 .17 .49
3q gain MB,32 SHH32 Poor No .14 .20 .80 —
6q gain MB31 Poor No .61 .30 .94 .19
Chr6(q) loss MB15,31,34 Good SGD .002 .90 .73 —
10q loss MB,32,35 SHH30 Poor SGS .012 .001 .23 .082
17p loss MB,26,32,36-40 SHH,30,32 Group 432 Poor SGS .003 .011 .030 .37
17q gain MB,31,32,35,40 SHH,30 Group 3,32 Group 432 Poor SGS .095 — .049 .72
Iso17q MB31,35,38,41 Poor SGS .005 — .008 .81
CDK6 amplification MB32,40 Poor No .51 .36 .17 .55
GLI2 amplification SHH30 Poor SGS < .001 .001 — —
MYC amplification MB31,42-46 Poor SGS < .001 — .011 .37
MYCN amplification MB,31,44 SHH,32 Group 432 Poor SGS .92 .002 — .24
OTX2 amplification MB47 Poor No .61 — .46 .77
NOTE. Bold font indicates significance; — indicates event not observed at sufficient frequency (n  1).
Abbreviations: chr, chromosome; iso, isochromosome; MB, medulloblastoma (across all subgroups); SGD, subgroup driven; SGS, subgroup specific.
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were copy-number profiled on the Affymetrix SNP6 platform (Santa Clara,
CA) to identify potential biomarkers.28 An independent validation set of 453
samples with clinical follow-up on a TMA was analyzed using FISH as previ-
ously described.53 Tumors were classified based on signature marker expres-
sion into molecular subgroups as previously described61; additional tumors
were classified based on cytogenetic aberrations using standard condi-
tional probability models. Subgroup affiliation was not available for 162
discovery samples. The validation set additionally included 50 WNT tu-
mors not on the TMA. Details on clinical data are listed in Data Supple-
ment 1, along with the availability of clinical and cytogenetic data. Nucleic
acid isolation, TMA construction, and -catenin mutation analysis were
performed as previously described.28
Prognostic Biomarker Identification
Cytogenetic events and CNAs were identified as previously described in
the discovery set.28 Subsequent to biomarker discovery, cross validation was
performed to estimate the reproducibility of the candidates in an independent
cohort, with multiple-hypothesis correction. Additionally, sample size esti-
mates for prospective trials of the biomarkers were calculated based on the
observed hazard ratios. Additional details are available in Data Supplement 1.
Statistical Analyses
Patient survivals were analyzed using the Kaplan-Meier method. The
predictive values of biomarkers were assessed through time-dependent re-
ceiveroperating characteristic analyses.Details of the survival analyses and risk
model selections are available in Data Supplement 1.
RESULTS
Prognostic Significance of Clinical Variables Within
Medulloblastoma Subgroups
Many priormedulloblastoma biomarker studies were limited by
sample size. Our study included 1,126 patients withmedulloblastoma
(673 discovery plus 453 validation patients; Data Supplement 1),
which is more than double the sample size of any prior medulloblas-
toma biomarker study, and it is one of few studies to include a valida-
tion cohort (Data Supplement 2). Although the discovery cohort
accumulated byMAGIC consists ofmedulloblastomas gathered from
43 different treating centers from around the world, the subgroup-
specific outcomes mirror those previously published, with good out-
comes for patientswithWNT,pooroutcomes for thosewithGroup3,
and intermediate outcomes for those with SHH andGroup 4medul-
loblastomas (Data Supplement 2), suggesting that the discovery co-
hort was a representative sample (Data Supplement 1).
To assess long-term survivors, patients withWNTmedulloblas-
toma were observed for up to 10 years, and only two deaths were
observed among 53 patients, both resulting from tumor recurrence
(Fig 1A; Appendix FigA1A, online only;Data Supplement 1). Among
those with SHH tumors, there were significantly better outcomes
among adult patients as compared with children or infants (Fig 1B;
Appendix Fig A1B, online only). Infants with Group 4 tumors had
significantly worse outcomes than children or adults (Fig 1B; Appen-
dix Fig A1B, online only), suggesting that radiation therapy is critical
in the treatment of Group 4 medulloblastoma. There was no consis-
tent association between sex and prognosis in any of the four sub-
groups (Data Supplement 1). Desmoplastic histology indicated a
more favorable prognosis than classic histology, which was more
favorable than anaplastic histology among SHH tumors (Data
Supplement 1). Large-cell/anaplastic histology was prognostically
significant for Group 3 medulloblastomas in the discovery cohort
but not in the validation cohort.
Metastatic status was not prognostic for patients with WNT
tumors; however, macroscopic metastasis (M2/M3) was consistently
associated with poor survival in all non-WNT subgroups, although
the clinical effect was modest among patients with Group 4 disease
(Fig 1C; Appendix Fig A1C, online only). Although the prognostic
significance of M0 disease as compared with M2/3 disease was con-
vincing across SHH,Group3, andGroup4 subgroups, the prognostic
significanceof isolatedM1disease (presenceof tumor cells in cerebro-
spinal fluid) was less clear (Fig 1C; Appendix Fig A1C, online only;
Data Supplement 1). IsolatedM1 disease was not consistently associ-
atedwith poor prognosis in the discovery or validation cohort for any
subgroup, which may be the result of small sample sizes. There were
no CNAs in any of the subgroups that were associated with an in-
creased risk of leptomeningeal dissemination (Data Supplement 1).
Overall, many clinical biomarkers continued to exhibit prognostic
significance when medulloblastoma was analyzed in a subgroup-
specific fashion (Data Supplement 1).
Subgroup and Metastatic Status Are the Most
Powerful Predictive Prognostic Biomarkers
Multivariable survival analyses were conducted to examine the
relative predictive value of clinical variables and subgroup affiliation.
Stepwise Cox regressions revealed that subgroup affiliation signifi-
cantly contributed to multivariable survival prediction, on top of a
regressionmodel already parameterized by sex, age, metastatic status,
and histology (Data Supplement 2). Furthermore, Cox proportional
hazardsmodels parameterizedwith both clinical biomarkers andmo-
lecular subgroups achieved higher accuracy in time-dependent re-
ceiver operating characteristic analyses (Data Supplements 1 and 2).
In isolation, each biomarker had modest prediction accuracy (Data
Supplement 2) compared with the complete multivariable model
(Data Supplement 2). In the complete model, the removal of meta-
static status and subgroup led to the greatest decreases in predictive
accuracy (Data Supplement 2). Taken together, these results suggest
that subgroup affiliation andmetastatic status are themost important
predictive biomarkers and that they make nonredundant contribu-
tions to the prediction of survival. We conclude that combining both
clinical and molecular biomarkers can enhance prediction of pa-
tient survival.
Subgroup Specificity of Published
Molecular Biomarkers
Several cytogenetic biomarkers havebeen associatedwithpatient
survival across medulloblastoma, but their prognostic value has sel-
dom been assessed in the context of medulloblastoma subgroups
(Table 1). Monosomy for chromosome (chr) 6 is associated with
improved survival acrossmedulloblastoma in toto (Fig 2A;Data Sup-
plement 1). However, the prognostic value of chr6 loss can be com-
pletely attributed to its enrichment in WNT medulloblastomas (Fig
2B; Data Supplement 1), because loss of chr6 has no prognostic value
among patients with WNT or non-WNT tumors when compared
with their respective controls with balanced chr6. We suggest that
monosomy 6 is a subgroup-driven biomarker; its prognostic signifi-
cance is driven by its enrichment in a particular subgroup, and it thus
holds no further significance in subgroup-specific analysis. Further-
more, these results would add a note of caution to usingmonosomy 6
as the lone diagnostic criterion forWNTmedulloblastoma, because it
was alsoobserved innon-WNTmedulloblastomas (seven [14%]of 49
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monosomy 6 medulloblastomas were not in WNT subgroup), and
monosomy 6 was only present in 42 (79%) of 53 WNT tumors. The
prognostic role of isochromosome (iso) 17q has been controversial;
for our cohort in toto, iso17qwas a statistically significant predictor of
poor outcome (Fig 2C).However, subgroup-specific analysis demon-
strated that iso17q was highly prognostic for Group 3 but not for
Group 4 medulloblastoma (Fig 2D), indicating that it is a subgroup-
specific molecular biomarker. Similarly, although 10q loss was a
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Fig 1. (A) Ten-year overall survival curves
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modestly significant predictor of poor outcome across medulloblas-
tomas (Fig 2E), its prognostic power was limited to SHH tumors in a
subgroup-specific analysis (Appendix Figs A2A and A2B, online
only).We conclude that determination of subgroup affiliation is cru-
cial in the evaluation and implementation of molecular biomarkers
for patients with medulloblastoma (Table 1; Data Supplement 1),
because some putative biomarkers are merely enriching for a specific
subgroup (ie, subgroup driven), whereas most others are significant
only within a specific subgroup (ie, subgroup specific).
Patients With SHH Tumors Can Be Stratified Into
Three Distinct Risk Groups
Weidentified11CNAs thatwereprognostically significant inour
SHH medulloblastoma discovery set (Appendix Figs A3A to A3D,
online only; Data Supplement 1) in univariable survival analyses.
Given the considerable number of candidates, the reproducibility of
the identified biomarkers was assessed through cross validation to
facilitate candidate prioritization, and the sample sizes required for
prospective trials were estimated for future studies (Data Supplement
1). Specific amplifications but not broad gains encompassing GLI2 or
MYCN were associated with poor prognosis (Appendix Figs A3A and
A3B, online only; Data Supplement 1). Loss of chr14q conferred
significantly inferior survival (Appendix Fig A3C, online only). There
was no minimal region of deletion on chr14 in patients with SHH
tumors (Data Supplement 1), and recent medulloblastoma rese-
quencing efforts have not identified any recurrent single-nucleotide
variants on chr14 in SHHmedulloblastoma.28,54,56,57,62 The presence
of chromothripsis (ie, chromosome shattering) was associated with
worse survival in those with SHH tumors (Appendix Fig A3D, on-
line only).17
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To integrate the individual biomarkers into a risk stratification
model, multivariable Cox analyses were performed on all significant
biomarkers. Throughmultiple stepwise regression procedures, a con-
sensus set of biomarkers was selected for inclusion in themodel in an
unbiasedmanner. The proposed risk stratification scheme represents
themodel thatwasmost consistentwithavailabledata in thediscovery
cohort, from amongmany possible alternatives (Figs 3A and 3B;Data
Supplement 1). GLI2 amplification, 14q loss, and leptomeningeal
dissemination identifiedhigh-andstandard-riskpatients. Specifically,
GLI2 amplification alone identifiedpatientswithpoorprognosis (Figs
3A and 3B; Data Supplement 1). Absence of these markers defined a
low-risk group of patients who exhibited survivorship reminiscent of
patients with WNT tumors. Importantly, none of the covariates,
particularly age and anaplastic histology, could explain the survival
differences observed among risk groups (Figs 3A and 3B; Data
Supplement 1). Direct application of the proposed risk stratifica-
tion scheme on the independent validation cohort yielded distinct
survivorship rates for the three risk groups, thereby validating the
model (Fig 3D).
Two additional stratification schemes were constructed using
only clinical biomarkers or only cytogenetic markers; however, the
proposed model, which combines both types of biomarkers,
yielded the highest accuracy (Fig 3C;Data Supplement 1). Further-
more, the accuracy of the combined risk model was drastically
reduced when applied across patients with non-SHH tumors, fur-
ther underscoring the importance of taking subgroup into consid-
eration during risk stratification. We conclude that by using two
molecular biomarkers (GLI2 and 14q FISH) and metastatic status,
we can practically and reliably predict prognosis for patients with
SHH medulloblastoma.
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Metastatic Status, Iso17q, and MYC
Amplification Identify High-Risk Patients With
Group 3 Medulloblastoma
In patients withGroup 3 tumors, iso17q andMYC amplification
remained the only cytogenetic markers associated with poor survival
(Appendix Figs A4A and A4B, online only), whereas chr8q loss and
chr1q gainwere the only goodprognosismarkers (Appendix FigA4C,
online only; Data Supplement 1). In multivariable survival analyses,
patients with metastasis, iso17q, or MYC amplification represented
the high-risk group (Figs 4A and 4B). Critically, absence of these
markers identified a population of patientswithGroup 3 tumorswith
favorable prognosis. The risk groups were not associated with any
clinical covariates, includingage (Figs4Aand4B;DataSupplement1).
Consistent with the findings in patients with SHH tumors, optimal
risk stratification of those with Group 3 tumors required the use of
both clinical and molecular prognostic markers, which have little
prognosticvalueoutsideofGroup3(Fig4C;DataSupplement1).Our
proposed risk stratification scheme was validated on the nonoverlap-
ping validation cohort using three molecular biomarkers (MYC, 17p,
and 17q FISH) andmetastatic status (Fig 4D).
Identification of a Low-Risk Group of Patients With
Metastatic Group 4 Medulloblastoma
Patients with Group 4 tumors with whole-chromosome loss of
chr11orgainof chr17, inaddition to10p loss, exhibitedbetter survival
under univariable Coxmodels (Appendix Fig A5A, online only; Data
Supplement1).Therewasnocytogeneticmarker associatedwithpoor
prognosis (Data Supplement 1). Specifically, neither MYCN gain nor
amplificationwas associatedwithpoorer survival in thosewithGroup
4 tumors, in stark contrast to patients with SHH tumors, reinforcing
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the distinction in their underlying biology (Appendix Fig A5B, online
only;DataSupplement1). Similarly,noneof thecytogeneticbiomark-
ers identified for patients with Group 3 tumors (eg, iso17q) had any
prognostic value for thosewithGroup4 tumors (Data Supplement 1).
After unbiased model selection, the consensus set of biomarkers re-
sulted in a risk stratification scheme inwhich leptomeningeal dissem-
ination identified high-risk patients with Group 4 tumors, except in
the context of chr11 loss or chr17 gain (Figs 5A and 5B). The biology
underlying chr11 losswas not apparent, because therewas noobvious
minimal common region of deletion (Data Supplement 1), nor were
there any recurrent single-nucleotide variants on chr11 reported. Pa-
tients with Group 4 tumors with either chr17 gain or chr11 loss,
irrespective of metastatic status, exhibited excellent survivorship in
both the discovery and validation cohorts (Figs 5B and 5D), and the
survival differences were not explainable by covariates (Data Supple-
ment 1). Consistent with other subgroups, the risk stratification
model using both clinical and molecular biomarkers achieved the
highest accuracy (Fig 5C).Critically, the cytogenetic biomarkers iden-
tified low-risk patients withGroup 4 tumors whowould be otherwise
designated as high risk by evidence of metastasis and/or anaplastic
histology; this finding could not be extrapolated to patients with SHH
orGroup3medulloblastoma (Figs 5A to5C;Data Supplement 1).We
conclude that through the use of three molecular biomarkers (chr11,
17p, and 17q FISH) and metastatic status, we can reliably predict the
prognosis of patients with Group 4medulloblastoma.
DISCUSSION
Current consensus identifies the existence of fourmajor subgroups of
medulloblastoma, with excellent prognosis for those with WNT tu-
mors, intermediate prognosis for those with SHH and Group 4 tu-
mors, and poor prognosis for those with Group 3 tumors.32,52
However, early evidence suggests clinical heterogeneity within these
core subgroups.7,30,63 Practical and reliable prognostication of risk
could allow for therapy intensification in high-risk children to im-
prove survival and de-escalation of therapy in low-risk children so as
to avoid the significant complications of therapy. However, the ma-
jority of publishedmedulloblastoma biomarker studies included only
small cohorts of patients, were not validated on nonoverlapping co-
horts, andwere performed in the presubgrouping era.Ourprognostic
study of 1,123 medulloblastomas, using techniques (eg, FISH) com-
patible with FFPE tissues, has identified clinically applicable risk strat-
ification for SHH, Group 3, and Group 4medulloblastomas.
We have demonstrated that medulloblastoma subgroup affilia-
tion is significantly more informative for predicting patient outcome
than existing clinical variables and that by incorporating subgroup
status with conventional clinical parameters for risk stratification, the
accuracy of survival prediction can be dramatically improved. More-
over, we have proposed, tested, and validated novel subgroup-specific
risk stratification models incorporating both clinical and molecular
variables. These models performed robustly both in the discovery
cohort consisting of heterogeneously treated groups of patients and in
a nonoverlapping validation cohort of patients treated at a single
institutionaccording to standardized treatmentprotocols.Becausewe
do not have detailed treatment information for patients in the discov-
ery cohort, it is possible that treatment protocols (type, duration, or
intensity) could have affected our results. We suggest that this possi-
bility canonlybe eliminated throughexaminationofour stratification
model in a sufficiently large prospective cohort. Although our study
used single-nucleotide polymorphism arrays or interphase FISH on
FFPE sections, it is possible that other approaches such as array com-
parative genomic hybridization could also be used to determine the
copy-number status of the six markers.64 Through the incorporation
of current clinical variables, subgroup affiliation, and our six copy-
number prognostic markers, as detailed in Data Supplement 1, rapid
prognostication is feasible in the setting of a regular hospital neuropa-
thology laboratory,making it a clinicallyutile technique.Becauseboth
subgrouping assays and prognostic FISH markers will need to be
performed in a Clinical Laboratory Improvement Amendments–
approved laboratory, we suggest that these assays be adopted and
optimized in most major neuro-oncology centers, whereas smaller
centersmay consider sending tissues for analysis at larger centers.Our
findings demonstrate the utility of incorporating tumor biology into
clinical decision making and offer a novel perspective on risk stratifi-
cation using FISH applicable on paraffin sections; thus, they could be
translated immediately into routine clinical practice.
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Fig A1. (A) Ten-year overall survival curves forWNTmedulloblastoma bymetastatic status. (B) Overall survival curves for age groupswithin Group 3 subgroup (infant, age 3 years;
child, age 3 to  16 years). (C) Overall survival curves for metastatic status for Group 4 subgroup. Numbers below x-axis represent patients at risk of event; statistical significance
evaluated by log-rank tests; hazard ratio (HR) estimates derived from Cox proportional hazards analyses. NS, not significant.
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Fig A2. Overall survival curves for chromosome 10q (chr10q) status in (A) SHH and (B) non-SHH medulloblastomas; survival differences evaluated by log-rank tests;
hazard ratio (HR) estimates derived from Cox proportional hazards analyses. NS, not significant.
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Fig A3. Clinical prognostication of patients with SHH medulloblastoma. Overall survival curves for (A) GLI2 copy-number status, (B) MYCN copy-number status, (C)
chromosome 14q (chr14q) status, and (D) chromothripsis status. HR, hazard ratio; NS, not significant.
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Fig A4. Clinical prognostication of patients with Group 3 medulloblastoma. Overall survival curves for (A) chromosome 17 (chr17) copy-number aberrations, (B) MYC
copy-number status, and (C) chr8q status. HR, hazard ratio; iso, isochromosome; NS, not significant.
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Fig A5. Clinical prognostication of patients with Group 4 medulloblastoma. Overall survival curves for (A) chromosome 11 (chr11) status and whole chr17 status and
(B) MYCN copy-number status. HR, hazard ratio; NS, not significant.
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